Aclara BioSciences Inc., of Hayward, Calif., named Bertram Rowland vice president and general counsel.
¿ AeroGen Inc., of Sunnyvale, Calif., elected to its board of directors Jean-Jacques Bienaime, CEO of SangStat Medical Corp.
¿ Affymetrix Inc., of Santa Clara, Calif., appointed Ronald Verdoorn executive vice president, global manufacturing.
¿ Alerge Medical Inc., of San Francisco, appointed Jan Barker vice president of operations. Lawrence Goldberg was retained in a consultative role to act as vice president of marketing and research.
¿ Alexion Pharmaceuticals Inc., of New Haven, Conn., named Nancy Motola vice president, regulatory affairs and quality assurance, and Paula Craft senior director, quality assurance and compliance.
¿ Alpha Therapeutic Corp., of Los Angeles, promoted Shinji Wada to vice president, international operations; Joseph D¿Arco, senior vice president, business development and licensing; and Armand Famiglietti, vice president, strategic planning and project management.
¿ AltaRex Corp., of Waltham, Mass., named Christopher Nicodemus senior vice president, medical and regulatory affairs.
¿ Amarillo Biosciences Inc., of Amarillo, Texas, appointed Kathleen Kelleher chief operating officer and vice president of business development.
¿ Ariad Pharmaceuticals Inc., of Cambridge, Mass., named Laurie Allen senior vice president, corporate development and legal affairs and general counsel.
¿ ArQule Inc., of Medford, Mass., appointed Stephen Hill president and CEO.
¿ AtheroGenics Inc., of Norcross, Ga., named Mark Colonnese vice president of finance and chief financial officer.
¿ Atlantic Pharmaceuticals Inc., of Raleigh, N.C., named as a director Martin Cleary, co-founder, president and CEO of CardioGene Therapeutics.
¿ Atugen Biotechnology GmbH, of Berlin, named Klaus Giese vice president of research.
¿ Aurora Biosciences Corp., of San Diego, promoted Thomas Klopack to senior vice president.
¿ Biogen Inc., of Cambridge, Mass., promoted James Mullen to president and chief operating officer. It also named Burt Adelman vice president, medical research; Michael Booney, vice president, sales and marketing; Joseph Davie, senior vice president, research; Sylvie Gregoire, vice president, regulatory affairs; and Mark Leuchtenberger, vice president, international.
¿ BiQuest Inc., of Houston, appointed Wayne Fritzsche as special advisor to the board of directors.
¿ Caliper Technologies Corp., of Mountain View, Calif., appointed Daniel Kisner president and CEO.
¿ Cardiac Science Inc., of Irvine, Calif., named Michael Gioffredi vice president, sales and marketing, and Barry Klegerman director of sales.
¿ Cell Therapeutics Inc., of Seattle, appointed Edward Kenney chief operating officer.
¿ Cellegy Pharmaceuticals Inc., of South San Francisco, appointed Jiro Hayashi special advisor business development in Japan.
¿ Cerus Corp., of Concord, Calif., named Robert Miller vice president of finance and chief financial officer.
¿ Clinicor Inc., of Austin, Texas, appointed Janice Hutt, D. Patrick Hankey and Ajay Ohir directors of business development.
¿ CombiChem Inc., of San Diego, named Mark Suto vice president, operations ¿ ChiroChem.
¿ Copernicus Therapeutics Inc., of Cleveland, named Maureen Costello director, pharmaceutical development.
¿ Cor Therapeutics Inc., of South San Francisco, added Patrick Broderick as senior vice president, general counsel and corporate secretary; Lee Rauch, senior vice president, corporate development; Anne Randolph, vice president, development; and Peter Roddy, vice president, finance.
¿ Cortex Pharmaceuticals Inc., of Irvine, Calif., appointed Robert Allnutt chairman of the board.
¿ CuraGen Corp., of New Haven, Conn., appointed Lloyd Smith to its scientific advisory board. Smith, a Romnes Faculty Fellow and professor of chemistry at the University of Wisconsin-Madison, is credited with developing the first fluorescent-based automated DNA sequencing instrument.